NCT07079735 Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
| NCT ID | NCT07079735 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Columbia University |
| Condition | CMV Viremia |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-09-12 |
| Primary Completion | 2028-01-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 150 participants in total. It began in 2025-09-12 with a primary completion date of 2028-01-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Eligibility Criteria
Inclusion Criteria: Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included. Exclusion Criteria: History of or suspected CMV disease within 6 months prior is excluded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07079735 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying CMV Viremia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07079735 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07079735 currently recruiting?
Yes, NCT07079735 is actively recruiting participants. Contact the research team at ar3262@cumc.columbia.edu for enrollment information.
Where is the NCT07079735 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT07079735 clinical trial?
NCT07079735 is sponsored by Columbia University. The trial plans to enroll 150 participants.